Global Respiratory Drugs Market 2018-2024

  • Product Code:
    RP-ID-10078078
  • Published Date:
    Mar 2019
  • Region:
    Global
  • Pages:
    113
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Respiratory disorders, which affect mechanisms of the respiratory system such as the lungs and airway, are a wide-ranging chronic disease with a diversity of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate muscles surrounding the bronchial tubes to suppress and open the airways.

Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress. During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.

Report Scope:

Report Category: Pharmacuticals / Healthcare

Therapy Type
Asthma
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Cystic Fibrosis
End-user
Hospitals
Ambulatory Care
Others
Regions
North America
Europe
Asia Pacific
Rest of the World
Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities
Table of Contents
1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Total Addressable Market 10
1.3 Industry Trends 10
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 12
2.3 Research Methodology 13
2.4 Report Assumptions 13
3 Market Snapshot 15
3.1 Market Definition – Infoholic Research 15
3.2 Segmented Addressable Market (SAM) 15
3.3 Importance of Respiratory Care 15
3.4 Trends of Respiratory Drugs Market 16
3.5 Related Markets 17
3.5.1 Oncology (Cancer) Drugs 17
3.5.2 Active pharmaceutical ingredients (APIs) 17
3.5.3 Over the counter drugs (OTC) 18
3.5.4 Diabetes Drugs 18
4 Market Outline 20
4.1 Pipeline Products of Respiratory Drugs by Major Companies 20
4.2 Market Segmentation 23
4.3 Porter 5(Five) Forces 24
4.4 PEST Analysis 25
5 Market Characteristics 26
5.1 Market Dynamics of Respiratory Drugs Market 26
5.1.1 Drivers 27
5.1.1.1 Increasing Aging Population 27
5.1.1.2 Rising prevalence of respiratory diseases 28
5.1.1.3 High prevalence of tobacco smoking 28
5.1.2 Opportunities 28
5.1.2.1 Supportive initiatives from government and other organizations 28
5.1.2.2 Huge pool of undiagnosed chronic obstructive pulmonary disease population 28
5.1.3 Restraints 29
5.1.3.1 Expiry of patents for blockbuster drugs 29
5.1.3.2 Complex drug development process 30
5.1.4 DRO – Impact Analysis 30
5.1.5 Key Stakeholders 31
6 Application: Market Size and Analysis 33
6.1 Overview 33
6.2 Asthma 34
6.3 Chronic Obstructive Pulmonary Disease (COPD) 35
6.4 Cystic Fibrosis 36
6.5 Allergic Rhinitis 37
6.6 Others 38
7 Regions: Market Size and Analysis 40
7.1 Overview 40
7.2 North America 41
7.2.1 Overview 41
7.2.2 United States 42
7.2.3 Canada 43
7.3 Europe 43
7.3.1 Overview 43
7.3.2 United Kingdom 44
7.3.3 Germany 44
7.3.4 France 45
7.4 APAC 45
7.4.1 Overview 45
7.4.2 India 45
7.4.3 China 46
7.4.4 Japan 46
7.5 Rest of the World 47
7.5.1 Overview 47
7.5.2 Middle East 48
7.5.3 Brazil 49
7.5.4 Mexico 49
8 Competitive Landscape 50
9 Vendor Profiles 53
9.1 Novartis AG 53
9.1.1 Overview 53
9.1.2 Business Unit 58
9.1.3 Geographic Presence 58
9.1.4 Business Focus 59
9.1.5 SWOT Analysis 59
9.1.6 Business Strategy 60
9.2 GlaxoSmithKline plc 62
9.2.1 Overview 62
9.2.2 Geographic Presence 67
9.2.3 Business Focus 67
9.2.4 SWOT Analysis 68
9.2.5 Business Strategy 69
9.3 Astra Zenca PLC 71
9.3.1 Overview 71
9.3.2 Geographic Presence 76
9.3.3 Business Focus 76
9.3.4 SWOT Analysis 77
9.3.5 Business Strategy 77
9.4 F.Hoffmann-La Roche Ltd. 78
9.4.1 Overview 78
9.4.2 Business Unit 82
9.4.3 Geographic Presence 83
9.4.4 Business Focus 84
9.4.5 SWOT Analysis 84
9.4.6 Business Strategy 85
9.5 Vertex Pharmaceuticals Inc. 86
9.5.1 Overview 86
9.5.2 Geographic Presence 89
9.5.3 Business Focus 89
9.5.4 SWOT Analysis 90
9.5.5 Business Strategy 90
10 Companies to Watch For 92
10.1 Boehringer Ingelheim GmbH 92
10.1.1 Overview 92
10.1.2 Highlights 93
10.2 Teva Pharmaceutical Industries Ltd. 94
10.2.1 Overview 94
10.2.2 Highlights: 96
10.3 Gilead Sciences Inc. 96
10.3.1 Overview 96
10.3.2 Highlights: 98
10.4 Bayer AG 99
10.4.1 Overview 99
10.5 Pfizer Inc. 101
10.5.1 Overview 101
10.5.2 Highlights 103
10.6 Bristol-Myers Squibb Co. 104
10.6.1 Overview 104
10.7 Merck & Co. 106
10.7.1 Overview 106
10.7.2 Highlights: 107
10.8 Sanofi 108
10.8.1 Overview 108
10.9 Mallinckrodt plc 109
10.9.1 Overview 109
Annexure 111
Abbreviations 111


Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Novartis AG, GlaxoSmithKline plc, Astra Zenca PLC, F.Hoffmann-La Roche Ltd. , Vertex Pharmaceuticals Inc. Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd. Gilead Sciences Inc. Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co. Merck & Co., Sanofi, Mallinckrodt plc
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports